On November 4, 2020 CTI BioPharma Corp. (Nasdaq: CTIC) reported an oral presentation supporting the Company’s pacritinib development program in graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, being held virtually December 5- 8, 2020 (Press release, CTI BioPharma, NOV 4, 2020, View Source [SID1234569902]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the presentation are as follows:

Abstract Title: Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I Trial Results
Session Name: Clinical Allogeneic Transplantation; Acute and Chronic GVHD, Immune Reconstitution Phase I and II Trials
Session Number: 722
Session Date: Sunday, December 6, 2020
Session Time: 9:30 a.m. – 11:00 a.m. PT
Presentation Time: 10:00 a.m. PT
Presenter: Dr. Joseph Pidala